Advances in cancer research / edited by Kenneth D. Tew and Paul B. Fisher.

Includes bibliographical references.

Intro; Title page; Table of Contents; Copyright; Contributors; Chapter One: Unconventional Approaches to Modulating the Immunogenicity of Tumor Cells; Abstract; 1 Text Elements; Acknowledgments; Chapter Two: A Theoretical Basis for the Efficacy of Cancer Immunotherapy and Immunogenic Tumor Dormancy: The Adaptation Model of Immunity; Abstract; 1 Introduction; 2 Outcome of Cancer Immunotherapies Inspired by the SNS and Danger Models; 3 Beyond the SNS and Danger Models: Tumor Escape and Immune Evasion; 4 Discovery and Modulation of Tumor Adaptation Receptors. 5 Immunogenic Dormancy of Occult Tumor Cells Through AdaptationAcknowledgments; Financial Support; Disclosures; Chapter Three: Bcl-2 Antiapoptotic Family Proteins and Chemoresistance in Cancer; Abstract; 1 Introduction; 2 Bcl-2 Family Proteins and Chemoresistance; 3 Potential Bcl-2 Inhibitors in Chemoresistance: Clinical Development; 4 Conclusions and Future Perspectives; Acknowledgments; Chapter Four: New Insights Into Beclin-1: Evolution and Pan-Malignancy Inhibitor Activity; Abstract; 1 General Introduction; 2 Introduction to Beclin-1; 3 Beclin-1 and Cancer. 4 Conclusions and Future DirectionsAcknowledgments; Supplementary Material; Chapter Five: Recent Advances in Nanoparticle-Based Cancer Drug and Gene Delivery; Abstract; 1 Introduction; 2 Types of Nanoparticles for Therapeutic Delivery; 3 Anticancer Therapeutics and Nanoparticle-Based Delivery Agents; 4 Nanoparticle-Based Codelivery of Drugs and Genes; 5 Stimuli-Responsive Drug Delivery; 6 Nanoparticle-Based Receptor-Targeted Delivery; 7 Conclusion and Prospects; Acknowledgments; Chapter Six: Evaluation of Resveratrol in Cancer Patients and Experimental Models; Abstract; 1 Introduction. 2 Resveratrol and Dietary Sources3 Resveratrol and Clinical Studies in Cancer Patients; 4 RES Mechanisms for Protection; 5 Nephroprotection by Resveratrol for Cisplatin; 6 Summary